-
Study aim
-
Determining the effect of Montelukast in the treatment of children with allergies to cystitis
-
Design
-
Clinical trial with control group, randomized, with parallel groups, without blinding, phase 3 on 56 patients, for randomization, block randomization method and online statistical software www.sealedenvelope.com will be used.
-
Settings and conduct
-
This study is a randomized clinical trial study that after obtaining the code of ethics from the ethics committee of Arak University of Medical Sciences, will be performed for six months in Amirkabir Hospital in Arak and by easy sampling. Blinding will not be performed in this study. Patients are randomly divided into control and intervention groups if there are inclusion criteria. Then the clinical symptoms of cystitis in patients will be evaluated daily for ten days.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: history of allergies, age 5 to 15 years, clinical diagnosis of cystitis. Exclusion criteria: fever, any complications associated with the disease
-
Intervention groups
-
In the control group, 28 patients received standard treatment for cystitis as treatment with the cefixime antibiotic at a dose of 8 mg / kg (Sobhan Daroo-Iran) daily for 10 days.
In the intervention group, 28 patients received standard cystitis treatment with cefixime antibiotic at a dose of 8 mg / kg daily for 10 days, in addition to the Montelukast (Sobhan Daru-Iran), orally and in the amount of 5 mg per day.
-
Main outcome variables
-
Dysuria, frequency, lower abdominal pain, urinary urgency, hematuria